KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Total Non-Current Liabilities: 2019-2025

Historic Total Non-Current Liabilities for Esperion Therapeutics (ESPR) over the last 5 years, with Sep 2025 value amounting to $807.9 million.

  • Esperion Therapeutics' Total Non-Current Liabilities was N/A to $807.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $807.9 million, marking a year-over-year change of. This contributed to the annual value of $420.8 million for FY2023, which is 19.26% up from last year.
  • As of Q3 2025, Esperion Therapeutics' Total Non-Current Liabilities stood at $807.9 million, which was up 4.50% from $773.2 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Total Non-Current Liabilities ranged from a high of $807.9 million in Q3 2025 and a low of $332.8 million during Q4 2021.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $420.8 million (2023), whereas its average is $508.6 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 383.85% in 2021, then decreased by 9.36% in 2022.
  • Over the past 5 years, Esperion Therapeutics' Total Non-Current Liabilities (Quarterly) stood at $332.8 million in 2021, then increased by 6.03% to $352.9 million in 2022, then climbed by 19.26% to $420.8 million in 2023, then increased by 20.86% to $431.0 million in 2024, then reached $807.9 million in 2025.
  • Its Total Non-Current Liabilities was $807.9 million in Q3 2025, compared to $773.2 million in Q2 2025 and $431.0 million in Q1 2024.